CME
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
July 14, 2023
Host: Charu Aggarwal, MD, MPH
Host: Joshua E. Reuss, MD
The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!